Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 16/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | AKT2 | P31751 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7256906 | 0.85 | TRPA1 (0.55) | ROCK2ROCK1AKT1AKT2TRPA1 | |
| SCHEMBL18378727 | 0.80 | AKT1 (0.47) | ROCK2ROCK1AKT1AKT2TRPA1 | |
| SCHEMBL20294499 | 0.78 | AKT2 (0.60) | ROCK2ROCK1AKT1AKT2PDCD1 | |
| SCHEMBL21451423 | 0.77 | IDO1 (0.53) | ROCK2ROCK1AKT1AKT2 | |
| SCHEMBL29324653 | 0.77 | AKT1 (0.44) | ROCK2ROCK1AKT1AKT2 | |
| SCHEMBL26078323 | 0.76 | ADRA1A (0.56) | — | |
| SCHEMBL19726594 | 0.75 | AKT1 (0.43) | ROCK2ROCK1AKT1AKT2TRPA1 | |
| SCHEMBL18375564 | 0.74 | AKT1 (0.42) | ROCK2ROCK1AKT1AKT2TRPA1 | |
| SCHEMBL607544 | 0.73 | CD274 (0.71) | PDCD1CD274 | |
| SCHEMBL23066174 | 0.72 | CD274 (0.46) | TRPA1PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210061831-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2021-03-04 | — | — | US | disclosed |
| US-9815818-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061831-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | ROCK2 501/4885ROCK1 784/4885AKT1 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.